Research published in JAMA Psychiatry demonstrated that long-acting, injectable, second-generation antipsychotic medication has tremendous potential to bring clinical stability to persons with first-episode schizophrenia. According to the authors, “long-acting medications are rarely used following a first episode of schizophrenia.”
Patients …
The Institute of Medicine has recently released a report entitled Cognitive Aging: Progress in Understanding and Opportunities for Action. This special report addresses “the emerging concept of cognitive aging, the importance of this issue for the nation’s public health, and …
Early detection in first-episode psychosis confers advantages for negative, cognitive, and depressive symptoms after 1, 2, and 5 years, but longitudinal effects have been unknown. A new article published in the American Journal of Psychiatry investigated the differences in symptoms …